

Think you know the truth about compounded “semaglutide”?

Taking compounded “semaglutide” can pose significant safety risks.¹

Nearly all of it is manufactured by foreign suppliers that create their own definitions of quality, and there are no clinical trials establishing that knockoff “semaglutide” is safe or effective.^{1,2}

The truth is that compounded “semaglutide” is NOT approved by the US Food & Drug Administration (FDA) and has not been reviewed for safety, effectiveness, and quality.¹



Actor portrayals

It can be risky to take, ineffective, or worse.

Impurities as high as 75%
that may pose immunogenicity risks^{3,a}

Accidental overdoses 5-20x
the intended dose⁴

Compounded products with 0%
semaglutide^{3,a}

^aIn some samples

Researchers discovered samples of compounded “semaglutide” that contained:



Dangerous Impurities



Unnecessary and Risky Ingredients



Banned and Unknown Substances⁵

Compounded “semaglutide” that melts under your tongue, dissolves against your cheek, or comes in a pill?

Don't count on them. When it comes to risk, the FDA has deemed that they can be “hazardous.”⁶



Compounded “semaglutide” is NOT approved by the FDA.



It's not reviewed.

Despite misleading advertising, the FDA does not review it for safety, effectiveness, or quality.

Safe? Not necessarily.

Without FDA approval, these products are now only made by compounding pharmacies that are not required to track, evaluate, or report side effects and adverse events.

Not proven.

No FDA approval means the benefits and risks are unknown.¹

It's illegal to make or sell.

FDA-approved medicines containing semaglutide are fully available nationwide, which makes it illegal to make or sell compounded “semaglutide” except for rare circumstances (such as a documented allergy to an inactive ingredient).⁷



Don't take our word for it. Experts are warning the public.

Government agencies, medical boards, and public health organizations are warning patients and healthcare providers about the risks of compounded “semaglutide.”

“The safety risks from continued mass compounding of GLP-1s are heightened because compounded GLP-1s rely on a supply of active pharmaceutical ingredients (API) from dangerous and illegal foreign sources.”⁸

—Center for Medicine in the Public Interest

“...there can be errors in compounding or contamination of the product because compounding pharmacies are not held to the same standards of larger drug manufacturers.”⁹

—National Capital Poison Center

**FDA-approved treatments exist.
Visit semaglutide.com to learn more.**

References

- 1 U.S. Food and Drug Administration (FDA). FDA's Concerns with unapproved GLP-1 drugs used for weight loss. Accessed May 2025. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>. May 16, 2025
- 2 Brookings Institution. The wild east of semaglutide. Accessed Dec. 2025. <https://www.brookings.edu/articles/the-wild-east-of-semaglutide/>. April 21, 2025.
- 3 Nomination from Covington & Burling LLP on behalf of Novo Nordisk Inc. to docket no. FDA-2017-N-2562. Accessed Dec. 2025. https://downloads.regulations.gov/FDA-2017-N-2562-0029/attachment_1.pdf. Oct. 22, 2024.
- 4 U.S. Food and Drug Administration (FDA). FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Accessed Dec. 2025. <https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded>. July 26, 2024.
- 5 Hach M, Englund DK, Mysling S, et al. Impact of manufacturing process and compounding on properties and quality of follow-on GLP-1 polypeptide drugs. *Pharm Res*. 2024; 41(10):1991-2014.
- 6 U.S. Food and Drug Administration (FDA). Drug products or categories of drug products that present demonstrable difficulties for compounding under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Accessed Dec. 2025. <https://www.regulations.gov/document/FDA-2023-N-0061-0001>. Mar. 20, 2024.
- 7 U.S. Food and Drug Administration (FDA). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Accessed Dec. 2025. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize>. April 28, 2025.
- 8 Center for Medicine in the Public Interest. FDA regulatory failures in enforcing limits on GLP-1 compounding puts patients at risk. Accessed Dec. 2025. <https://cmpi.org/in-the-news/fda-regulatory-failures-in-enforcing-limits-on-glp-1-compounding-puts-patients-at-risk>. July 21, 2025.
- 9 National Capital Poison Center. What is Ozempic? Accessed Dec. 2025. <https://www.poisson.org/articles/can-ozempic-help-me-lose-weight>. Dec. 23, 2023.